The following Incubator/BioBAT companies have internships available for qualified candidates. Please contact the organization for details regarding their openings.

Applied Biological Laboratories Inc.

Applied Biological Laboratories Inc. is a biotechnology company committed to research, development, manufacturing and distribution of scientifically validated natural products.

Contact: Nazlie Latefi, PhD

Biotia, Inc.

Biotia is a health tech company, launched from Cornell Tech and Weill Cornell Medicine, that leverages DNA sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Their mission is to fight infectious disease by deploying the leading reference library of microbes worldwide.

Contact: Courtney Hager

International AIDS Vaccine Initiative (IAVI) , Inc.

IAVI's Vaccine Design and Development Laboratory (DDL) is a versatile facility designed to create novel immunogens, develop viral vectors, evaluate potency and advance promising candidates to clinical evaluation. The DDL has also established common preclinical standards for the vaccine field. Their goals are to understand the basis of naturally evoked, broadly neutralizing antibodies against HIV and other Emerging Infectious Diseases (EID) such as, but not limited to, Lassa fever, Marburg virus, and Covid-19.

Contact: Joanne De Stefano

Interstate Environmental Commission

The Interstate Environmental Commission (IEC) is a tri-state water and air pollution control agency committed to protecting, conserving, and restoring the environment in the Interstate Environmental District, particularly in the area of water quality. IEC seeks to achieve this goal through cooperation, regulation, coordination, and mutual dialogue between government and citizens in the Tri-State Region.

Contact: Evelyn Powers

Mirimus, Inc.

Mirimus is a high-tech business with the expertise in RNAi technologies required for development of superior tools for potent gene silencing, both in cells and animal models. Its advanced RNAi technologies are critical for the generation of animal models that can pave the way drugs are developed by pin-pointing potential toxicities and preventing harmful side-effects of therapeutics in patients. Mirimus is also engaged in the design, development and pioneering of new CRISPR/Cas9 genome editing technologies to develop advanced human disease models that are crucial for the preclinical evaluation of new therapeutics.

Contact: Mima Kovacevic